DSPE-PEG-NHS is a linear heterobifunctional PEGylation reagent with a DSPE phospholipid and an activated carboxylic acid NHS ester. It is a useful self-assembling reagent to prepare PEGylated liposome or micelle while also providing a NHS group for conjugation with amine-containing molecules. It is useful in targeted drug delivery with the lipid bilayer to improve drug solubility. PEG provides stealth property, extend circulation half-life and reduce non-specific protein binding or cell adhesion. The succinimidyl NHS ester bioconjugates to targeting molecules including antibody, aptamer, protein, and peptide.
DSPE-PEG-NHS, full name is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000, NHS ester] (sodium salt); CAS number: 2410279-87-5
Molecular weight: MW of PEG was measured by MALDI-MS or GPC. PDI (polydispersity index) of our linear PEG is 1.02-1.05 with very narrow MW distribution. The number of repeating ethylene oxide units (CH2CH2O) or the degree of polymerization is calculated dividing the PEG MW by 44 (44 is the molecular mass of one repeating unit).
Solubility: Soluble in chloroform, methylene chloride, DMF, and DMSO. Lipid PEGs have enhanced solubility in alcohols and slightly soluble in ether with increasing solubility in ether with decreasing MW of PEG.
Density: PEG density is approximately 1.125 g/mL
Physical form: PEG products generally appear as white or off-white powder, and for very low MW linear PEG such as MW 1k or less, it may appear as wax-like, semi-solid material due to the low MW and the type of functional groups.
Storage condition: PEG product shall be stored in the original form as received in a freezer at -20C or lower for long term storage. Stock solution of PEG reagents that do not contain oxygen or moisture sensitive functional groups may be temporarily stored in a refrigerator or ambient temperature for multiple days. Stock solution should avoid repeated freeze-and-thaw cycles. See Documents section for detailed storage and handling conditions.
1. Anti prostate cancer using PEGylated bombesin containing, cabazitaxel loading nano-sized drug delivery system, Journal Drug Development and Industrial ,Volume 42, 2016 – Issue 12, Text.
Click here to view an expanded list of hundreds of publications citing Creative PEGWorks products.